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Mycobacterium abscessus lung disease is difficult to treat and has been considered a strong relative contraindication to lung transplantation.
We performed double lung transplantation in three cystic fibrosis patients with ongoing, and a fourth with recent treatment for Mycobacterium
abscessus lung infection. Despite prolonged antibiotic courses and adjustment of immunosuppressive therapy the first three patients developed
skin infection and abscesses. At follow-up after 1, 3, 5 and 7 years respectively no patient had evidence ofM abscessus infection and all had stable
lung function. Lung transplantation in patients with M abscessus lung infection is feasible but may involve severe complications.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Lung transplantation; Mycobacterium; Complication; Abscess1. Introduction
Lung infection with Mycobacterium abscessus, a multi-
resistant rapidly growing mycobacteria, is difficult to treat and
has become an increasing problem in patients with cystic fibrosis
(CF) [1,2]. Fatal infection has been described after lung trans-
plantation [3–5], and pre-transplant colonisationwithMabscessus
has thus been considered as a strong relative contraindication to
lung transplantation [4].
2. Methods
This was a retrospective observational study including all
patients referred for lung transplantation since the initiation of☆ This work has in part been presented at the 32nd European Cystic Fibrosis
Conference, Brest, France, 2009.
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1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.03.008the Gothenburg Lung Transplant Program in 1990. The Pro-
gram has increased over time and by Dec 31 2009 a total of 397
(8.3% CF) single- double- or heart–lung transplantations had
been performed.No patient has been declined due toMabscessus
lung infection and only 4 patients, all CF, were infected with
M abscessus. Standard immunosuppression at the time for our
first patient was antithymocyte globuline (ATG) 2 mg/kg for
induction followed by extra doses of 1.5 mg/kg the following
days if CD3 in serum was N0.05×109/L and until target serum
level for cyclosporine A (CyA) or tacrolimus (Tac) was reached.
Tac was chosen only if intolerable side effects from CyA were
expected. Standard target trough serum levels for CyA was
350 ng/mL for three months, 300 ng/mL months 3–6, and there-
after 200 (150) ng/mL. The corresponding levels for Tac was
15–20 ng/mL, 12–15 ng/mL and 10–12 ng/mL respectively.
Mycophenolate mofetil (MMF) 1–1.5 g twice daily and pred-
nisolon 0.3 mg/kg body weight for two months, 0.2 mg/
kg months 2–6 and thereafter 0.1 mg/kg. The first patient was
started according to the protocol but for the next three pa-
tients we aimed for lower target ranges. All patients receivedd by Elsevier B.V. All rights reserved.
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aeruginosa, Stenotrophomonas maltophilia and Staphylococcus
aureus for at least 10 days postoperatively, as well as nystatin,
gancyclovir or valgancyclovir for cytomegalovirus (CMV) pro-
phylaxis for three (Recipient+) or six (Donor+/Recipient−)
months and trimethoprim-sulphametoxasol (TmS) for Pneumo-
cystis jiroveci.
3. Case reports
See Table 1 and Fig. 1 for overview.
3.1. Patient 1
A 10-year-old boy, at time for transplantation, with pan-
creatic insufficiency, CF-related diabetes mellitus and a gastro-
stomy for enteral nutrition. He was chronically infected with
P aeruginosa and S aureus and during the last two years also
with M abscessus (both smooth and rough colony morphology
(SCM, and RCM), occasionally smear positive). Treatment with
doxycycline and azitromycin was initiated six months pre-
transplant, while amikacin was withheld for post-transplant use.
Double lung transplantation was performed through sterno-
tomy and on cardiopulmonary bypass (CPB) from start. The
lungs were in part adherent to the thoracic wall and pleura and
there were abundant of large hilar lymph glandules. Standard
immunosuppression with ATG, CyA, MMF and prednisolonTable 1
Demographic and clinical data.
Patient Gender/Age BMI* Pre-operative
microbiology
Surgical procedure
Pleural adhesions§
Enlarged lymph
glandules§
Bleeding§
Immuno
1 M/10 17** MA (+)
PA, SA
Sternotomy, BLTx, CPB
++
++
++
ATG
CyA, M
2 F/28 18** MA −
PA, SA
Clamshell, BLTx CPB§§
++
+++
+++
CyA, M
3 F/26 16** MA −
PA, SA
(AF)
Sternotomy, BLTx, CPB
+++
+
+
Tac, Az
4 M/20 17*** MA −
SM, SA
BAT, SSLT
+
++
+
ATG
Tac, MM
BMI = bodymass index, *gastrostomy in all, **diabetesmellitus requiring insulin, ***
intermittently, − smear negative, PA = Pseudomonas aeruginosa, SM = Stenotropho
pleurectomy left, BLTx = bilateral lung transplantation, CPB = cardiopulmonary
transplantation, ATG = anti thymocyte globuline, CyA = Cyclosporine A, MMF = m
ceftazidim, Ami = amikacin, EMB = ethambutol, Mero = meropenem, Az = azitromy
month, ICU = intensive care unit, CMV = cytomegalovirus, Patients 1–3 received at l
patients 2 and 3 for 6 months. For additional treatment and prophylactic antibiotics swas given, as well as ceftazidim i.v., nystatin, Tobi® inhalation,
gancyclovir intravenously and TmS. An early rejection episode
was treated with methylprednisolon. Due to severe side effects,
including leukopenia, nausea and anorexia, MMF was stopped
early and gancyclovir after three months.
Disseminated mycobacterial infection developed, starting a
few weeks postoperatively as a deep infection in the surgical
incision and osteomyelitis in the sternum. Tobi® was switched
to amikacin and ethambutol, meropenem and azitromycin was
added.
At six weeks fevers developed and the sternum was unstable,
requiring surgical revision and vacuum-assisted closure of the
wound. At three months a new revision of the wound and skin
transplantation was performed. The boy was discharged after
five months but readmitted one month later with CMV pneu-
monitis requiring intensive care, followed by repeated rejection
episodes. During the first year, starting three weeks postoper-
atively, almost all cultures from skin, sternum, blood and bron-
choalveolar lavage (BAL) were positive for M abscessus, and
granulomas were seen in transbronchial biopsies. After the first
year all cultures have been negative for M abscessus. Anti-
mycobacterial therapy included amikacin intravenously for
three months followed by inhalation for two years, ethambutol
and a macrolide for two years. In addition intravenous gamma-
globuline was started at four months as immunologic tests had
revealed poor qualitative IgG function, interpreted as a T-cell-
dependant B-cell defect.-supression CMV
D/R
Postoperative
antibiotics
Major complications
first year
Follow-up
years
MF, S
+/− a)Tobi®+Cefta
b) Ami+EMB+
Mero+Az/Clar
Rejection×2
CMV infection—ICU,
severe MA infection,
vacuum pump,
skin transplantation
7
MF, S −/+ a) Cefta+Ami
b) Az+EMB
MA skin abscesses,
anorexia,
renal dysfunction
5
a, S +/− a) Mero+Ami
b) Az
MA skin abscesses
Aspergillus empyema,
gastroparesis
3
F, S
+/− a) Mero Pneumonia at 10 months 1
impaired glucose tolerance,MA=Mycobacterium abscessus; (+) smear positive
monas maltophilia, SA = Staphylococcus aureus, §grading 0 to +++, §§previous
bypass, BAT = bilateral anterior thoracotomy, SSLT = single sequential lung
ycophenolate mofetil, S = steroids, Tac = tacrolimus, Aza = azathioprin, Cefta =
cin, Clar = clarithromycin, a) started immediately postop., b) started within first
east two anti-mycobacterial antibiotics for a prolonged time; patient 1 for 2 years,
ee text.
Fig. 1. Patients 1–4. Pre-operative CT scans of the chest.
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tion and FEV1 has increased with age and is stable at 92%
predicted (BOS stage 0). The height and weight are −2.5 SD
compared to −1 SD pre-transplant. Chronic complications
include decreased kidney function, impaired hearing and pain
problems.3.2. Patient 2
A 28-year-old woman with pancreatic insufficiency, CF-
related diabetes mellitus, body mass index (BMI) of 18 and a
gastrostomy. Previous pneumothorax on the left side required
surgery. She was chronically infected with S aureus, P aerugi-
nosa, and during the last four years pre-transplant also with M
abscessus (RCM, smear negative). She was on azitromycin con-
tinuously. Double lung transplantation was performed through a
clamshell incision. The lungs were adherent to the thoracic wall
and pleura and there were abundant of enlarged hilar lymph
glandules. The procedure was started without but completed on
CPB due to bleeding problems and circulatory instability during
dissection of the native lungs. Cyclosporine, azathioprin and
prednisolon were given but ATG was omitted. She was also
immediately started on ceftazidim, amikacin, nystatin, valgan-
cyclovir and TmS. During the first year P aeruginosa airway
infection required repeated antibiotic courses. She also received
two courses of amphotericin B inhalation therapy for Aspergil-
lus fumigatus airway colonisation and TmS for Pneumocystis
jiroveci repeatedly in BAL. Disseminated infection with ab-
scesses in the surgical wound and on the buttocks developed
within a few weeks. M abscessus was cultured from skin and
pleura during the first three months and in BAL during the whole
first year, and hereafter occasionally from skin (site of previous
abscesses). Treatment included amikacin intravenously for six
months, ethambutol for five months, and, azitromycin and gam-
maglobuline continuously. After five years she has no evidence
of mycobacterial infection, her lung function is stable with FEV1
of 2.0 L (57% predicted and BOS stage 1) but she is under as-
sessment for kidney transplantation due to renal failure.
3.3. Patient 3
A 26-year-old woman with pancreatic insufficiency, CF-
related diabetes mellitus, BMI of 16 and a gastrostomy. She
was chronically infected with S aureus, P aeruginosa and has
had occasional cultures positive for A Fumigatus. During the last
five years pre-operatively she was treated with rifampicin and
azitromycin forM abscessus (RCM, smear negative) lung infec-
tion. Double lung transplantation was performed trough a
sternotomy and starting without, but after difficult dissection of
adherent lungs, continuing on CPB. She was started on Tac,
prednisolon and MMF, which was soon switched to azathioprin
due to side effects. ATG was omitted. She was also immediately
started on meropenem, amikacin, nystatin, valgancyclovir and
TmS. After a few weeks abscesses gradually developed in the
incision, requiring surgical revision. During the first six months
all cultures from skin and BAL grew M abscessus. Treatment
included amikacin for six months, azitromycin and gamma-
globuline continuously. Exophiala dermatitidis in sputum early
postoperatively was treated with caspofungine for two weeks.
After six months an A fumigatus empyema developed. It re-
solved with drainage and three months combination antifun-
gal therapy. Three years postoperatively she has no signs of
mycobacterial infection and the lung function is stable with
FEV1 of 64% predicted (BOS 0). Chronic complications are
275M. Gilljam et al. / Journal of Cystic Fibrosis 9 (2010) 272–276decreased kidney function, severe gastroparesis and chronic
pain.
3.4. Patient 4
A 20-year-old man with pancreatic insufficiency, impaired
glucose tolerance, allergic asthma, gastroesophageal reflux dis-
ease, gluten intolerance, BMI of 17 and a gastrostomy. He was
chronically infected with S maltophilia and had two years pre-
operatively completed a ten-month eradication treatment with
amikacin, ofloxacin, clarithromycin and ethambutol due to
repeated growth of M abscessus (RCM, smear negative) in
sputum cultures.
Double lung transplantation was uncomplicated and per-
formed through bilateral anterior thoracotomies, thus avoiding
cutting through bone. He was given ATG for induction, Tac,
MMF and prednisolon and also meropenem, nystatin, valgan-
cyclovir and TmS. There were no early postoperative compli-
cations. A pneumonia after ten months resolved on therapy and
after one year he is stable with an FEV1 of 82% (BOS 0).
4. Discussion
M abscessus is ubiquitous in soil and water and can cause
skin and lung infection, central nervous system disease [6] and
disseminated disease in immune-compromised hosts [4].
Since the first discouraging reports, successful treatment ofM
abscessus infection after lung transplantation has been described
[7,8]. There was no indication of pre-transplant colonisation
in these cases. In an international survey only 2/17 patients with
M abscessus infection after lung transplantation were colonised
pre-transplant. Both responded to medical therapy on recurrence
postoperatively but died from causes not attributed to M ab-
scessus [9]. Good short and long-term outcome in patients with
pre-transplant infection has however been reported recently
[10,11].
It is important to have a close collaboration with the micro-
biological laboratory regarding isolation, identification and sen-
sitivity testing [2,12,13]. All our patients harboured the rough
phenotype which is considered more virulent. A switch from
smooth to rough type may occur [12,14]. Ideally, eradication
therapy forM abscessus should be attempted pre-transplant, but
adding long-time treatment with multiple drugs may be compli-
cated in the CF-patient with severe disease, nutritional problems
and significant co-infection with other bacteria requiring re-
peated intravenous antibiotic courses. Waiting time on the list
varies between centers and it is difficult to plan anti-mycobac-
terial therapy for a defined time pre-transplant until surgery.
With prolonged treatment there is a risk of further increase of
antibiotic resistance and adverse drug effects. All our patients
were malnourished and had CF-related diabetes mellitus/
impaired glucose tolerance, and whether this contributed to
acquisition of mycobacterial infection we may speculate. Pre-
transplant treatment against M abscessus was administered at
the local hospital, after discussions with experts in mycobacte-
rial disease and with the transplant center. There were no pub-
lished treatment guidelines for M abscessus in CF available butrecently successful eradication therapy has been reported [15].
We however doubt that patients 1–3 would have managed to
complete the suggested therapy.
Aseptic surgical methods should be used. The extent of
pulmonary, hilar and pleural changes, as well as the surgeon's
familiarity with different methods, will influence the surgical
approach. Good access for careful debridement is necessary if
the lungs are adherent to the thoracic wall. CPB should be
avoided, if possible, due to the risk of bleeding problems. Single
sequential lung transplantation through bilateral thoracotomies
has the advantage not cutting through bone and thus reduc-
ing the risk of osteomyelitis. The incision can, if necessary,
be extended to a clamshell incision. We used this approach for
patient 4 with good result. He was however the patient with the
least scarring and CPB was not required.
Given the severe infectious problems for patient 1, we choose
to refrain from ATG for patients 2 and 3. ATG is a powerful
suppressor of the T-cell-function, which is crucial in the defence
against mycobacteria. For patient 4, who had been culture nega-
tive for M abscessus, we choose to give ATG for induction in
order to allow a more gradual increase of CyA and thus sparing
the kidney. MMF/azathioprin and Prednisolon were given as
routine, while serum target levels for Tac/CyA was aimed for
approximately 25% lower than standard in patients 2–4. It was
however difficult to maintain steady drug serum levels in all
patients. Three/4 patients were CMV mis-matched and all were
colonised with other microbes, requiring specific treatment. The
choice to “wait and see” or to start with multiple drugs imme-
diately postoperatively has to be decided based on the severity
of M abscessus infection pre-transplant and on the surgical out-
come. Only one of our patients was occasionally smear positive
and all had responded well to pre-transplant treatment against
S aureus, P aeruginosa and S maltophilia. It was difficult to
elucidate to which extent the mycobacteria contributed to disease
pre-transplant. Other factors, such as kidney function, nausea/
vomiting and nutritional problems, the total therapeutic burden,
and the risk of chronic complications from drug side effects have
to be taken into account. All our patients have impaired hearing
and decreased kidney function now.
Result had revealed poor qualitative IgG function in patient 1
and our impression is that he stabilised on intravenous gammaglo-
buline. All patients had normal or high IgG levels pre-transplant
but unfortunately IgG levels were not checked post-transplant.
We suggest that quantitative and qualitative immunoglobuline
function should be checked [16] post-transplant in patients with
severe infectious problem.
5. Conclusion
Lung transplantation in patients with M abscessus lung in-
fection is feasible but may involve severe complications and
M abscessus lung infection should be considered as a relative
contraindication for lung transplantation. We believe that pre-
transplant eradication therapy should be attempted, that optimi-
sation of nutrition and diabetes pre- and post-transplant, as well
as tapering of immunosuppressive therapy as soon as possible,
is of utmost importance for a good outcome. Most patients will
276 M. Gilljam et al. / Journal of Cystic Fibrosis 9 (2010) 272–276require treatment with multiple antibiotics for prolonged time
and the therapy should be initiated immediately post-transplant,
but there is no consensus on which protocol to use. The thera-
peutic role of gammaglobuline has not been defined but substi-
tution therapy should be considered in patients with impaired
quantitative or qualitative immunoglobuline function. We sug-
gest that induction therapy with ATG should be avoided in
patients with activeM abscessus lung disease and that Tac/CyA
target serum levels should be decreased 25–30% compared
to standard. And finally, the vacuum pump is a helpful tool for
treatment of infected surgical wounds with granulomas.
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